Metformin and the incidence of prostate cancer in patients with type 2 diabetes

Cancer Epidemiology Biomarkers and Prevention

Volumn 20, Issue 2, 2011, Pages 337-344

  Azoulay, Laurent ^a,b   Dell'Aniello, Sophie ^a   Gagnon, Bruno ^b   Pollak, Michael ^b   Suissa, Samy ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GLUCOSIDASE INHIBITOR; BIGUANIDE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GUAR GUM; MEGLITINIDE; METFORMIN; ORAL ANTIDIABETIC AGENT; SULFONYLUREA DERIVATIVE; THIAZOLIDINE DERIVATIVE;

ADULT; ARTICLE; CANCER INCIDENCE; CANCER RISK; CASE CONTROL STUDY; CONTROLLED STUDY; DIABETIC PATIENT; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRESCRIPTION; PRIORITY JOURNAL; PROSTATE CANCER; RISK REDUCTION;

AGED; CASE-CONTROL STUDIES; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; FOLLOW-UP STUDIES; GREAT BRITAIN; HUMANS; HYPOGLYCEMIC AGENTS; INCIDENCE; MALE; METFORMIN; MIDDLE AGED; PROGNOSIS; PROSTATIC NEOPLASMS; RISK FACTORS; SENSITIVITY AND SPECIFICITY;

EID: 79951592967     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-10-0940     Document Type: Article

References (52)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300.
2. Fitzpatrick JM, Schulman C, Zlotta AR, Schroder FH. Prostate cancer: a serious disease suitable for prevention. BJU Int 2009; 103:864-70.
3. Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003;349:215-24. (Pubitemid 36859473)
4. Andriole GL, Bostwick DG, Brawley OW, Gomella LG, Marberger M, Montorsi F, et al. Effect of dutasteride on the risk of prostate cancer. N Engl J Med 2010;362:1192-202.
5. Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD. Metformin and reduced risk of cancer in diabetic patients. BMJ 2005;330:1304-5. (Pubitemid 40813563)
6. Bowker SL, Majumdar SR, Veugelers P, Johnson JA. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care 2006;29:254-8. (Pubitemid 44106500)
7. Libby G, Donnelly LA, Donnan PT, Alessi DR, Morris AD, Evans JM, et al. New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care 2009;32:1620-5.
8. Landman GW, Kleefstra N, van Hateren KJ, Groenier KH, Gans RO, Bilo HJ, et al. Metformin associated with lower cancer mortality in type 2 diabetes: ZODIAC-16. Diabetes Care 2010;33:322-6.
9. Bowker SL, Yasui Y, Veugelers P, Johnson JA. Glucose-lowering agents and cancer mortality rates in type 2 diabetes: assessing effects of time-varying exposure. Diabetologia 2010;53:1631-7.
10. Currie CJ, Poole CD, Gale EA. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 2009; 52:1766-77.
11. Li D, Yeung SC, Hassan MM, Konopleva M, Abbruzzese JL. Antidiabetic therapies affect risk of pancreatic cancer. Gastroenterology 2009;137:482-8.
12. Bodmer M, Meier C, Krahenbuhl S, Jick SS, Meier CR, et al. Long-term metformin use is associated with decreased risk of breast cancer. Diabetes Care 2010;33:1304-8.
13. Murtola TJ, Tammela TL, Lahtela J, Auvinen A. Antidiabetic medication and prostate cancer risk: a population-based case-control study. Am J Epidemiol 2008;168:925-31.
14. Wright JL, Stanford JL. Metformin use and prostate cancer in Caucasian men: results from a population-based case-control study. Cancer Causes Control 2009;20:1617-22.
15. Alexander GC, Sehgal NL, Moloney RM, Stafford RS. National trends in treatment of type 2 diabetes mellitus, 1994-2007. Arch Intern Med 2008;168:2088-94.
16. Shaw RJ, Lamia KA, Vasquez D, Koo SH, Bardeesy N, Depinho RA, et al. The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science 2005;310:1642-6. (Pubitemid 41780780)
17. Pollak M. Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 2008;8:915-28.
18. Zakikhani M, Dowling RJ, Sonenberg N, Pollak MN. The effects of adiponectin and metformin on prostate and colon neoplasia involve activation of AMP-activated protein kinase. Cancer Prev Res 2008;1:369-75.
19. Ben SI, Laurent K, Loubat A, Giorgetti-Peraldi S, Colosetti P, Auberger P, et al. The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene 2008;27:3576-86. (Pubitemid 351793803)
20. Huang X, Wullschleger S, Shpiro N, McGuire VA, Sakamoto K, Woods YL, et al. Important role of the LKB1-AMPK pathway in suppressing tumorigenesis in PTEN-deficient mice. Biochem J 2008;412:211-21. (Pubitemid 351758227)
21. Wang W, Guan KL. AMP-activated protein kinase and cancer. Acta Physiol 2009;196:55-63.
22. Kasper JS, Liu Y, Giovannucci E. Diabetes mellitus and risk of prostate cancer in the health professionals follow-up study. Int J Cancer 2009;124:1398-403.
23. Walley T, Mantgani A. The UK General Practice Research Database. Lancet 1997;350:1097-9. (Pubitemid 27437871)
24. Garcia Rodriguez LA, Perez GS. Use of the UK General Practice Research Database for pharmacoepidemiology. Br J Clin Pharmacol 1998;45:419-25. (Pubitemid 28227341)
25. Jick H, Jick SS, Derby LE. Validation of information recorded on general practitioner based computerised data resource in the United Kingdom. BMJ 1991;302:766-8.
26. Lawrenson R, Williams T, Farmer R. Clinical information for research; the use of general practice databases. J Public Health Med 1999;21: 299-304. (Pubitemid 29446069)
27. Lawrenson R, Todd JC, Leydon GM, Williams TJ, Farmer RD. Validation of the diagnosis of venous thromboembolism in general practice database studies. Br J Clin Pharmacol 2000;49:591-6. (Pubitemid 30326559)
28. Jick SS, Kaye JA, Vasilakis-Scaramozza C, Garcia Rodriguez LA, Ruigomez A, Meier CR, et al. Validity of the general practice research database. Pharmacotherapy 2003;23:686-9. (Pubitemid 36539051)
29. Suissa S. Novel approaches to pharmacoepidemiology study design and statistical analysis. In: Strom B, editor. Pharmacoepidemiology . 4th ed. Chichester, England: John Wiley & Sons; 2005. p. 811-29.
30. Essebag V, Platt RW, Abrahamowicz M, Pilote L. Comparison of nested case-control and survival analysis methodologies for analysis of time-dependent exposure. BMC Med Res Methodol 2005;5:5.
31. Essebag V, Genest J Jr, Suissa S, Pilote L. The nested case-control study in cardiology. Am Heart J 2003;146:581-90. (Pubitemid 37281701)
32. Bostwick DG, Burke HB, Djakiew D, Euling S, Ho SM, Landolph J, et al. Human prostate cancer risk factors. Cancer 2004;101:2371-490. (Pubitemid 39505434)
33. Giovannucci E, Rimm EB, Stampfer MJ, Colditz GA, Willett WC. Diabetes mellitus and risk of prostate cancer (United States). Cancer Causes Control 1998;9:3-9. (Pubitemid 28048654)
34. Zhu K, Lee IM, Sesso HD, Buring JE, Levine RS, Gaziano JM, et al. History of diabetes mellitus and risk of prostate cancer in physicians. Am J Epidemiol 2004;159:978-82. (Pubitemid 38608275)
35. Rodriguez C, Patel AV, Mondul AM, Jacobs EJ, Thun MJ, Calle EE, et al. Diabetes and risk of prostate cancer in a prospective cohort of US men. Am J Epidemiol 2005;161:147-52. (Pubitemid 40096789)
36. Calton BA, Chang SC, Wright ME, Kipnis V, Lawson K, Thompson FE, et al. History of diabetes mellitus and subsequent prostate cancer risk in the NIH-AARP Diet and Health Study. Cancer Causes Control 2007;18:493-503. (Pubitemid 46684823)
37. Werny DM, Saraiya M, Gregg EW. Prostate-specific antigen values in diabetic and nondiabetic US men, 2001-2002. Am J Epidemiol 2006;164:978-83.
38. Muller H, Raum E, Rothenbacher D, Stegmaier C, Brenner H. Association of diabetes and body mass index with levels of prostate-specific antigen: implications for correction of prostate-specific antigen cutoff values? Cancer Epidemiol Biomarkers Prev 2009;18: 1350-6.
39. Waters KM, Henderson BE, Stram DO, Wan P, Kolonel LN, Haiman CA, et al. Association of diabetes with prostate cancer risk in the multiethnic cohort. Am J Epidemiol 2009;169:937-45.
40. Atchison EA, Gridley G, Carreon JD, Leitzmann MF, McGlynn KA. Risk of cancer in a large cohort of U.S. veterans with diabetes. Int J Cancer 2011;128:635-43.
41. Barrett-Connor E, Khaw KT, Yen SS. Endogenous sex hormone levels in older adult men with diabetes mellitus. Am J Epidemiol 1990;132:895-901. (Pubitemid 20363668)
42. Barrett-Connor E. Lower endogenous androgen levels and dyslipidemia in men with non-insulin-dependent diabetes mellitus. Ann Intern Med 1992;117:807-11.
43. Cox ME, Gleave ME, Zakikhani M, Bell RH, Piura E, Vickers E, et al. Insulin receptor expression by human prostate cancers. Prostate 2009;69:33-40.
44. Ma J, Li H, Giovannucci E, Mucci L, Qiu W, Nguyen PL, et al. Prediagnostic body-mass index, plasma C-peptide concentration, and prostate cancer-specific mortality in men with prostate cancer: a long-term survival analysis. Lancet Oncol 2008;9:1039-47.
45. Ray WA. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol 2003;158:915-20. (Pubitemid 37323253)
46. Benoit SR, Fleming R, Philis-Tsimikas A, Ji M. Predictors of glycemic control among patients with Type 2 diabetes: a longitudinal study. BMC Public Health 2005;5:36.
47. Kristal AR, Arnold KB, Neuhouser ML, Goodman P, Platz EA, Albanes D, et al. Diet, supplement use, and prostate cancer risk: results from the prostate cancer prevention trial. Am J Epidemiol 2010;172:566-77.
48. Friedenreich CM, McGregor SE, Courneya KS, Angyalfi SJ, Elliott FG. Case-control study of lifetime total physical activity and prostate cancer risk. Am J Epidemiol 2004;159:740-9. (Pubitemid 38656131)
49. Jones BA, Liu WL, Araujo AB, Kasl SV, Silvera SN, Soler-Vila H, et al. Explaining the race difference in prostate cancer stage at diagnosis. Cancer Epidemiol Biomarkers Prev 2008;17:2825-34.
50. United Kingdom Census 2001. United Kingdom population by ethnic group. Office for National Statistics, Newport, UK; 2001.
51. Felmeden DC, Lip GY. Antihypertensive therapy and cancer risk. Drug Saf 2001;24:727-39. (Pubitemid 32848352)
52. Strom BL, Melmon K. The use of pharmacoepidemiology to study beneficial drug effects. In: Strom BL, editor. Pharmacoepidemiology. 2nd ed. Chichester, England: John Wiley & Sons; 1994. p. 611-28.